What the trial was testing
The Measure Up 2 enrolled 912 patients with atopic dermatitis. The study was sponsored by AbbVie and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
78% had 75% eczema improvement on upadacitinib 30 mg vs. 12-30% on comparison.
JAMA Dermatology · 2023 · NCT03607422
These findings — that achieved 75% eczema clearance on upadacitinib 30 mg in adolescents — were published in the JAMA Dermatology and represent the headline result of the study.
Researchers tracked outcomes across 912 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Upadacitinib (Rinvoq) is FDA-approved and available now for moderate-to-severe atopic dermatitis in patients 12 and older. It is taken once daily by mouth. Side effects to watch for include infections, blood clots, and lab abnormalities. Ask a dermatologist about whether it fits and what monitoring is needed.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.